Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer

PURPOSE: Triple negative breast cancer (TNBC) is characterized by the presence of immune cells in the tumor microenvironment, however, the response to single-agent immune checkpoint inhibitor (ICI) therapy is modest. Preclinical models have demonstrated that intratumoral regulatory T cells (T(regs))...

Descripción completa

Detalles Bibliográficos
Autores principales: Anders, Carey K, Woodcock, Mark G, Van Swearingen, Amanda E D, Moore, Dominic T, Sambade, Maria J, Laurie, Sonia, Robeson, Alexander, Kolupaev, Oleg, Cuaboy, Luz A, Garrett, Amy L, McKinnon, Karen, Cowens, Kristen, Bortone, Dante, Calhoun, Benjamin C, Wilkinson, Alec D, Carey, Lisa, Jolly, Trevor, Muss, Hyman, Reeder-Hayes, Katherine, Kaltman, Rebecca, Jankowitz, Rachel, Gudena, Vinay, Olajide, Oludamilola, Perou, Charles, Dees, E Claire, Vincent, Benjamin G, Serody, Jonathan S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical Trials Monitor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819787/
https://www.ncbi.nlm.nih.gov/pubmed/35121644
http://dx.doi.org/10.1136/jitc-2021-003427

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819787/
https://www.ncbi.nlm.nih.gov/pubmed/35121644
http://dx.doi.org/10.1136/jitc-2021-003427

Ejemplares similares